Keith I. Block, MD, is an internationally recognized expert in integrative oncology. Referred to by many as the “father of integrative oncology,” Dr. Block combines cutting-edge conventional treatment with individualized and scientifically-based complementary and nutraceutical therapies. In 1980, he co-founded with Penny B. Block, Ph.D. the Block Center for Integrative Cancer Treatment in Evanston, Illinois, the first such facility in North America, and serves as its Medical and Scientific Director.
The field of integrative oncology was formally recognized by the launching of Integrative Cancer Therapies (ICT). In 2000, Dr. Block was invited by Sage Science Press to be the founding Editor-in-Chief of this peer-reviewed journal, the first medical journal devoted to exploring the research and science behind integrative oncology. In 2007, ICT was accepted by Thomson Scientific for inclusion in the Science Citation Index Expanded™.
Dr. Block is currently Director of Integrative Medical Education at the University of Illinois College of Medicine at Chicago. Additionally, he is the Scientific Director of the Institute for Integrative Cancer Research and Education, where he has collaborated with colleagues at the University of Illinois at Chicago, the University of Texas M.D. Anderson Cancer Center in Houston and Bar Ilan University in Israel. Dr. Block is also on Dr. Andrew Weil’s faculty at the Arizona Center for Integrative Medicine, the University of Arizona College of Medicine. In 2005, he was appointed to the National Cancer Institute’s Physician Data Query (PDQ) Cancer CAM Editorial Board, on which he continues to serve today.
Dr. Block has published more than 75 scientific papers and numerous articles relevant to nutritional and integrative oncology. Recent papers were published in Cancer Treatment Reviews 2007, International Journal of Cancer 2008, Molecular Interventions 2008, Journal of National Cancer Institute 2008 and the Breast Journal 2009.
The Block model of individualized integrative oncology continues to set the standard for the practice of this comprehensive approach to cancer treatment in the U.S.